Targeting the Urokinase Receptor in Glioblastoma Multiforme

靶向多形性胶质母细胞瘤中的尿激酶受体

基本信息

批准号：
8501950
负责人：
STEVEN L. GONIAS
金额：
$ 32.16万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN DIEGO
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-03-01 至 2018-02-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8501950
关键词：
Applications Grants Basic Science Binding Sites Biological Models Brain Cell Line Cell Survival Cell physiology Cells Chemotherapy-Oncologic Procedure Critiques Diffuse Disease remission Doxycycline Drug Targeting EGF gene Epidermal Growth Factor Receptor Erlotinib Event Excision Exons Exposure to Failure Financial compensation Foundations Gefitinib Gene Amplification Genomic Instability Glioblastoma Goals Grant Growth Human Immunofluorescence Microscopy Integrins Laboratories Ligand Binding Malignant - descriptor Malignant Neoplasms Malignant neoplasm of brain Membrane Proteins Molecular Multiprotein Complexes Mus Mutation Neuraxis Operative Surgical Procedures PTEN gene Pathway interactions Patients Pharmaceutical Preparations Phenotype Phosphorylation Physiology Play Population Protein Tyrosine Kinase Proteins Publishing Quantum Dots Receptor Cell Receptor Gene Receptor Signaling Recurrence Regulation Research Project Grants Resistance Role STAT5B gene Signal Pathway Signal Transduction Specimen Study models Suggestion System Technology Testing Therapeutic Time Tumor Suppressor Proteins Tyrosine Kinase Inhibitor Urokinase Plasminogen Activator Receptor Work Xenograft procedure cancer cell cell growth cell motility design drinking water drug development effective therapy epidermal growth factor receptor VIII extracellular human FPRL1 protein in vivo neoplastic cell outcome forecast preclinical study promoter protein function public health relevance receptor therapeutic development therapeutic target transcription factor tumor tumor growth tumor microenvironment tumor progression

项目摘要

DESCRIPTION (provided by applicant): Glioblastoma multiforme (GBM) is an aggressive CNS malignancy, which is rarely curable. Diffuse brain invasion is a hallmark of this cancer. At the molecular level, the EGF receptor (EGFR) plays a central role in determining the physiology of many GBMs. EGFR gene amplification is common in GBM and frequently accompanied by an in-frame deletion of exons 2-7, which yields a truncated and constitutively active form of the receptor (EGFRvIII). Because of the profound effects of the EGFR and EGFRvIII on GBM cell physiology, EGFR-selective tyrosine kinase inhibitors (TKIs) and other EGFR-targeting therapeutics have been used to treat these tumors. Efficacy has been demonstrated; however, GBMs typically escape from control. We have identified the urokinase-type plasminogen activator receptor (uPAR) as a cell-signaling receptor that may become activated to support GBM cell growth and survival when EGFR signaling is neutralized or when GBM cells are treated with EGFR-targeting therapeutics. Activation of the uPAR cell-signaling system may increase GBM cell migration and invasion. In GBM cells, in which EGFRvIII is expressed, crosstalk pathways involving EGFRvIII and uPAR may be essential to activate the mitogenic transcription factor, STAT5B, and actualize a highly aggressive phenotype. Similar crosstalk pathways also may occur when the EGFR is amplified in the absence of EGFRvIII. The goal of this research project is to characterize the role of uPAR as a receptor that synergizes with the EGFR in GBM cells and as a receptor that may allow GBMs to escape from control in patients that are treated with EGFR-targeting therapeutics. Understanding uPAR mechanisms in GBM cells will facilitate rational design of uPAR-targeting therapeutics that could be used independently or in combination with EGFR-targeting drugs in patients with GBM. In Aim 1, we will study multiple model systems, including human GBMs that are propagated as xenografts, to test the hypothesis that activation of uPAR signaling constitutes an important pathway by which GBM cells escape from control by EGFR-targeting therapeutics. In Aim 2, we will characterize uPAR-EGFR crosstalk, at the molecular level in GBM cells, and test candidate therapeutic approaches for neutralizing this crosstalk. In Aim 3, we test whether inadvertent activation of the uPA-uPAR system, in GBM cells treated with EGFR-targeting therapeutics, induces phenotypic changes favoring cell migration and invasion. In Aim 4, we explore the relationship between uPAR and the EGFR in surgical specimens of primary and recurrent human GBMs. We also will apply quantum dot immunofluorescence microscopy to probe for evidence of uPAR signaling in human GBM specimens, at the single-cell level. Although this project has a basic science foundation, our objectives are highly translational. Ultimately, our goal is to complete the pre-clinical studies necessary to justify targeting uPAR for therapeutics development in GBM.

描述（由申请人提供）：多形性胶质母细胞瘤（GBM）是一种侵袭性中枢神经系统恶性肿瘤，很少能治愈。弥漫性脑侵犯是这种癌症的标志。在分子水平上，EGF 受体 (EGFR) 在决定许多 GBM 的生理学方面发挥着核心作用。 EGFR 基因扩增在 GBM 中很常见，并且经常伴有外显子 2-7 的框内删除，从而产生截短且组成型活性的受体形式 (EGFRvIII)。由于 EGFR 和 EGFRvIII 对 GBM 细胞生理学的深远影响，EGFR 选择性酪氨酸激酶抑制剂 (TKI) 和其他 EGFR 靶向疗法已被用于治疗这些肿瘤。功效已得到证实；然而，GBM 通常会失控。我们已经确定尿激酶型纤溶酶原激活剂受体（uPAR）是一种细胞信号受体，当 EGFR 信号传导被中和或 GBM 细胞接受 EGFR 靶向治疗时，它可能被激活以支持 GBM 细胞的生长和存活。 uPAR 细胞信号系统的激活可能会增加 GBM 细胞的迁移和侵袭。在表达 EGFRvIII 的 GBM 细胞中，涉及 EGFRvIII 和 uPAR 的串扰途径可能对于激活有丝分裂转录因子 STAT5B 并实现高度侵袭性表型至关重要。当 EGFR 在不存在 EGFRvIII 的情况下被扩增时，也可能发生类似的串扰途径。该研究项目的目标是确定 uPAR 作为一种与 GBM 细胞中的 EGFR 协同作用的受体的作用，以及作为一种可能使接受 EGFR 靶向治疗的患者的 GBM 逃脱控制的受体的作用。了解 GBM 细胞中的 uPAR 机制将有助于合理设计 uPAR 靶向疗法，这些疗法可以单独使用或与 EGFR 靶向药物联合用于 GBM 患者。在目标 1 中，我们将研究多个模型系统，包括作为异种移植物繁殖的人类 GBM，以检验以下假设：uPAR 信号传导的激活构成 GBM 细胞逃离 EGFR 靶向治疗药物控制的重要途径。在目标 2 中，我们将在 GBM 细胞的分子水平上表征 uPAR-EGFR 串扰，并测试中和这种串扰的候选治疗方法。在目标 3 中，我们测试是否无意中激活了 uPA-uPAR 系统在接受 EGFR 靶向治疗的 GBM 细胞中诱导有利于细胞迁移和侵袭的表型变化。在目标 4 中，我们探讨了原发性和复发性人类 GBM 手术标本中 uPAR 和 EGFR 之间的关系。我们还将应用量子点免疫荧光显微镜在单细胞水平上探索人类 GBM 样本中 uPAR 信号传导的证据。尽管该项目具有基础科学基础，但我们的目标具有高度转化性。最终，我们的目标是完成必要的临床前研究，以证明针对 GBM 疗法开发的靶向 uPAR 的合理性。